|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-6-23
|
|
pubmed:abstractText |
To evaluate toxicity and outcomes in patients with primary glioblastoma (GB) treated with postoperative radiochemotherapy (RCHT) with temozolomide (TMZ) comparing two dose regimens.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
999-1005
|
|
pubmed:dateRevised |
2008-12-31
|
|
pubmed:meshHeading |
pubmed-meshheading:18258384-Adult,
pubmed-meshheading:18258384-Aged,
pubmed-meshheading:18258384-Antineoplastic Agents, Alkylating,
pubmed-meshheading:18258384-Brain Neoplasms,
pubmed-meshheading:18258384-Combined Modality Therapy,
pubmed-meshheading:18258384-Dacarbazine,
pubmed-meshheading:18258384-Dose-Response Relationship, Drug,
pubmed-meshheading:18258384-Drug Administration Schedule,
pubmed-meshheading:18258384-Female,
pubmed-meshheading:18258384-Germany,
pubmed-meshheading:18258384-Glioblastoma,
pubmed-meshheading:18258384-Humans,
pubmed-meshheading:18258384-Male,
pubmed-meshheading:18258384-Middle Aged,
pubmed-meshheading:18258384-Prevalence,
pubmed-meshheading:18258384-Radiotherapy,
pubmed-meshheading:18258384-Risk Assessment,
pubmed-meshheading:18258384-Risk Factors,
pubmed-meshheading:18258384-Survival Analysis,
pubmed-meshheading:18258384-Survival Rate,
pubmed-meshheading:18258384-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
|
|
pubmed:affiliation |
Neuro-Radiation Oncology Research Group, Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
